George Mathew, Mathew Thomas, Vundum Jonathon, Mani Anita, Baluwala Israfil
Medcial Oncology, Calvary Mater, Newcastle, AUS.
University of Newcastle, School of Medicine and Public Health, Newcastle, AUS.
Cureus. 2025 Jun 15;17(6):e86093. doi: 10.7759/cureus.86093. eCollection 2025 Jun.
Small cell lung cancer (SCLC) is an aggressive malignancy with historically poor survival outcomes, especially in patients with significant comorbidities. This report presents a rare case of a 65-year-old woman with limited-stage SCLC and JAK2-positive essential thrombocythemia (ET), who subsequently developed multiple malignancies including papillary thyroid carcinoma, right-sided colon adenocarcinoma, and basal cell carcinoma. Despite serious complications such as subdural hematoma and intra-abdominal bleeding, the patient remains clinically stable over a decade after her initial diagnosis. Genetic testing revealed no hereditary cancer syndromes, suggesting a potential role of chronic inflammation and prior therapies in her cancer trajectory. This case underscores the importance of early aggressive therapy, vigilant long-term follow-up, and multidisciplinary coordination in managing complex oncologic and hematologic conditions.
小细胞肺癌（SCLC）是一种侵袭性恶性肿瘤，历来生存预后较差，尤其是在有严重合并症的患者中。本报告介绍了一例罕见病例，一名65岁患有局限期小细胞肺癌和JAK2阳性原发性血小板增多症（ET）的女性，随后发展为多种恶性肿瘤，包括乳头状甲状腺癌、右侧结肠腺癌和基底细胞癌。尽管出现了硬膜下血肿和腹腔内出血等严重并发症，但该患者在初次诊断后的十多年里临床情况一直稳定。基因检测未发现遗传性癌症综合征，提示慢性炎症和既往治疗在其癌症发展过程中可能起作用。该病例强调了在管理复杂的肿瘤和血液疾病时早期积极治疗、长期密切随访以及多学科协作的重要性。
